project id: TCGA-ESCA; case submitter id: TCGA-V5-AASW; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.94; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.66; rna integrity number: 8.8; age at index: 72; days to birth: -26571; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; age at diagnosis: 26571; ajcc clinical m: M0; ajcc clinical n: N1; ajcc clinical stage: Stage IIIA; ajcc clinical t: T3; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 282.0; icd 10 code: C15.9; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Esophagus, NOS; synchronous malignancy: No; tissue or organ of origin: Esophagus, NOS; tumor grade: Not Reported; treatment or therapy: yes; alcohol history: No; is ffpe: false; composition: Not Reported; days to sample procurement: 0; initial weight: 20.0; portion submitter id: TCGA-V5-AASW-01A-11; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0;